Max Roessler

425 total citations
11 papers, 238 citations indexed

About

Max Roessler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Max Roessler has authored 11 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Max Roessler's work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Max Roessler is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Max Roessler collaborates with scholars based in Germany, Switzerland and Austria. Max Roessler's co-authors include Michael Krainer, Christoph Zielinski, Robert Zeillinger, Dietmar Pils, Peter Horak, Sandra Tomek, Reinhard Horvat, Ingrid Pribill, Berta Moritz and Ulrich Jaehde and has published in prestigious journals such as Journal of Clinical Oncology, Gynecologic Oncology and Molecular Cancer Research.

In The Last Decade

Max Roessler

11 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Roessler Germany 5 153 91 58 46 35 11 238
Diptee Kulkarni United States 10 192 1.3× 103 1.1× 41 0.7× 29 0.6× 35 1.0× 13 304
Tieying Dong China 8 171 1.1× 125 1.4× 120 2.1× 58 1.3× 39 1.1× 9 324
Jianchang Wei China 7 168 1.1× 122 1.3× 143 2.5× 52 1.1× 50 1.4× 13 314
Venkatesh Kancherla Switzerland 6 72 0.5× 101 1.1× 55 0.9× 30 0.7× 24 0.7× 8 188
Zhiqun Zhou United States 11 203 1.3× 154 1.7× 47 0.8× 74 1.6× 21 0.6× 20 379
Katrin Madjar Germany 7 97 0.6× 77 0.8× 41 0.7× 40 0.9× 52 1.5× 14 187
Chia C. Portera United States 10 195 1.3× 234 2.6× 51 0.9× 60 1.3× 27 0.8× 19 385
Shunfang Liu China 9 176 1.2× 59 0.6× 97 1.7× 26 0.6× 39 1.1× 28 285
Gopichand Pendurti United States 6 133 0.9× 98 1.1× 48 0.8× 76 1.7× 36 1.0× 11 287
Zhefeng Xiao China 8 208 1.4× 71 0.8× 62 1.1× 28 0.6× 44 1.3× 14 293

Countries citing papers authored by Max Roessler

Since Specialization
Citations

This map shows the geographic impact of Max Roessler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Roessler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Roessler more than expected).

Fields of papers citing papers by Max Roessler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Roessler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Roessler. The network helps show where Max Roessler may publish in the future.

Co-authorship network of co-authors of Max Roessler

This figure shows the co-authorship network connecting the top 25 collaborators of Max Roessler. A scholar is included among the top collaborators of Max Roessler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Roessler. Max Roessler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Joerger, Markus, Max Roessler, Karina Hettwer, et al.. (2024). Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy. Tumor Biology. 46(s1). S191–S206. 2 indexed citations
2.
Joerger, Markus, Max Roessler, Karina Hettwer, et al.. (2024). Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy – A CEPAC-TDM biomarker substudy. Tumor Biology. 46(s1). S355–S367. 1 indexed citations
3.
Kanefendt, Friederike, JJ Swen, F. Sörgel, et al.. (2017). Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer. CPT Pharmacometrics & Systems Pharmacology. 6(9). 604–613. 19 indexed citations
4.
Salamone, Salvatore J., Ulrich Jaehde, Lothar Mueller, et al.. (2017). Prospective, multi-center study of 5-fluorouracil (5-FU) therapeutic drug management (TDM) in metastatic colorectal cancer (mCRC) patients treated in routine clinical practice.. Journal of Clinical Oncology. 35(4_suppl). 650–650. 3 indexed citations
5.
Wilhelm, Martin, Lothar Mueller, Michael Craig Miller, et al.. (2016). Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. Clinical Colorectal Cancer. 15(4). 381–388. 54 indexed citations
6.
7.
Kunzmann, Volker, Michael Craig Miller, Stefan Holdenrieder, et al.. (2015). A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens.. Journal of Clinical Oncology. 33(15_suppl). 3542–3542. 3 indexed citations
8.
Joerger, Markus, Joachim von Pawel, Stefanie Kraff, et al.. (2015). Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient.. Journal of Clinical Oncology. 33(15_suppl). 8051–8051. 3 indexed citations
9.
Horak, Peter, Dietmar Pils, Max Roessler, et al.. (2005). Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. Gynecologic Oncology. 97(2). 514–518. 18 indexed citations
10.
Horak, Peter, Dietmar Pils, Ingrid Pribill, et al.. (2005). Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer. Molecular Cancer Research. 3(6). 335–343. 122 indexed citations
11.
Roessler, Max. (1967). Optimal aerodynamic-propulsive maneuvering for the orbital plane change of a space vehicle.. Journal of Spacecraft and Rockets. 4(12). 1678–1680. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diptee Kulkarni Breakdown of academic impact, for papers by Tieying Dong Breakdown of academic impact, for papers by Jianchang Wei Breakdown of academic impact, for papers by Venkatesh Kancherla Breakdown of academic impact, for papers by Zhiqun Zhou Breakdown of academic impact, for papers by Katrin Madjar Breakdown of academic impact, for papers by Chia C. Portera Breakdown of academic impact, for papers by Shunfang Liu Breakdown of academic impact, for papers by Gopichand Pendurti Breakdown of academic impact, for papers by Zhefeng Xiao
Rankless by CCL
2026